CUTISS receives 25 million francs from investors

Schlieren ZH – CUTISS has concluded its first Series C financing with 25 million Swiss francs. This enables the life science company in the field of regenerative medicine to enter Phase 3 clinical trials for its personalized skin tissue therapy.

CUTISS has received 25 million Swiss francs in a first Series C financing round. It was led by the family office of Ticino-based Italian healthcare investor Giammaria Giuliani and a North American family represented by Shiloh Advisors.

According to a press release issued by the life sciences company CUTISS, which was founded in 2016 and is based in the Bio-Technopark Schlieren-Zurich, this first deal enables the company to enter Phase 3 clinical trials for its personalized skin therapy denovoSkin. It was only in April 2024 that the spin-off from the University of Zurich and Zurich Children's Hospital announced the positive results of its Phase 2 study in people with severe and extensive skin injuries. In addition, the funds will reportedly be used to advance the commercialization and clinical readiness of the machine developed by CUTISS for the production of its personalized human skin tissue therapy denovoSkin.

"This funding will enable us to continue working at full speed to achieve the key milestones in our development," CUTISS CEO and co-founder Dr. Daniela Marino is quoted as saying. "The recent positive results of the phase 2 clinical trial for denovoSkin have encouraged us to develop further innovations in the field of regenerative medicine." According to Marino, the Series C financing round has not yet been completed. "We invite other investors to support our mission." ce/mm

View full article